The acute LD50 for MIS was increased from 1-54 to 1-90 g/kg after phenobarbitone pretreatment and 1-78 g/kg after phenytoin pretreatment. In addition, pretreatment with either compound shortened the duration of the MIS-induced decrease in body temperature.
Tumour/plasma and brain/plasma concentration ratios for MIS, and tumour/ plasma ratios for Ro 05-9963 were very similar, but the brain/tumour ratios for Ro 05-9963 were considerably lower. Tissue/plasma ratios were unaltered by pretreatment with phenobarbitone or phenytoin.
The acute LD50 for MIS was increased from 1-54 to 1-90 g/kg after phenobarbitone pretreatment and 1-78 g/kg after phenytoin pretreatment. In addition, pretreatment with either compound shortened the duration of the MIS-induced decrease in body temperature.
These data suggest that pretreatment with microsomal-enzyme-inducing agents may reduce the toxicity of MIS without affecting the radiosensitization. The significance of these findings for the mechanism of MIS toxicity is also discussed. many drugs can be altered by the previous or simultaneous administration of other agents (Conney, 1967; Morselli et al., 1974; Grahame-Smith, 1977) . Drug interactions with antineoplastic agents have been reviewed recently (Warren & Bender, 1977) .
Phenobarbitone and phenytoin are known to be potent inducers of microsomal drug-metabolizing enzymes in rodents (e.g. Marshall & McLean, 1969; Gerber & Arnold, 1969) and in man THE HYPOXIC cell radiosensitizer misonidazole (1-(2-nitroimidazol-1-yl)-3-methoxypropan-22-ol; Ro 07-0582, Roche Laboratories; NSC-261037; MIS) is currently undergoing clinical trials at several radiotherapy centres. Previous studies have shown the importance of MIS disposition kinetics in governing the toxic and therapeutic effects (Dische et al., 1977; Saunders et al., 1978; Workman et al., 1978a; Brown et al., 1979) .
It is well known that the effects of Correspondence to: Dr P. Workman, AIRC Clinical Oncology and Radiotherapeuties Unit, Tlle Medical School, Hills Road, Cambridge CB2 2QH. (Pirttiaho et al., 1978) . Both compounds and/or other drugs with enzyme-inducing side-effects are required by many cancer patients also receiving MIS.
In the present paper we describe an investigation of the effects of phenobarbitone and phenytoin pretreatment on the pharmacokinetics and toxicity of MIIS in mice. The study was designed to ask the following questions:
( (Conney, 1967) . Mice wN-eighed 20-30 g.
T'umours EMT6 Tunmour. The originial EMT6 tumour wvas described by Rockwell et al. (1972) . The subline used in the present work was the recently re-designated EMT6/Ca/ VJAC line, previously known as, EMT6/V7J/ AC (Twentyman & Bleehen, 1975 MC6B Tumour. The origin and history of the methylcholanthrene-induced sarcoma MC6B lhas been described by Sikora et al. (1977) . For the present studies the tumour was used after 8 (B1O/MC 6B/8/0) or 9 (BlO/ MC 6B/9/0) continuous passages in vivo, wvith no passages in vitro.
The following procedure w-as used to produce solid tumours. Two tumours (O10mm diameter) Awere excised aseptically from donor mice and minced finelv wvith scissors. The tumour fragments were placed in 150 ml Hanks' balanced salt solution containing 0 05%0 trypsin, and agitated on a magnetic stirrer for 40 min. The mixture Awas then filtered through cotton gauze, and the filtrate centrifuged at 3000 g for 10 min. The cell pellet wvas resuspended in full medium to neutralize trypsin, centrifuged and resuspended in Hanks' solution (HBSS) then centrifuged again and finally resuspended in HBSS at 106 cells/ml. The viable yield was 106-107 cells/tumour. BlO mice wvere inoculated as described above for EMT6. Mice wvere used 9 days after inoculation, -when their tumours were in the same size range as the EMT6 tumours.
For both the MC6B and EMT6 tumours, tumour volumes in mice pretreated with phenobarbitone or phenytoin were often up to 10% lower than the saline controls, but this was usually not significant (P > 0 05). From our previous studies wve wrould not expect such small differences to affect tumour drug concentration (WA'orkman et al., in preparation).
Drugs
Supplies of MIS and its 0-demethylated metabolite Ro 05-9963 (1-(2-nitroimidazol-1-yl)-2, 3-propandiol) wvere provided by Roche Laboratories (Welwyn Garden City). Phenvtoin (5.5-diphenylhydantoin, sodium salt) was obtained from Sigma Chemical Company (Poole) and phenobarbitone (sodium salt) from BDH Laboratories (Poole). Sodium pentobarbitone was obtained from May & Baker Limited (Dagenhanm) as a 60 mg/ml solution for injection (Sagatal).
Drug pretreatnment regimes
Details of the phenobarbitone and phenytoin pretreatment regimes are summarized in Table 1 . The pretreatment regimes wAere similar to those described previously (Marshall & McLean. 1969 : Gerber & Arnold, 1969 to induce microsomal drug-metabolizing enzymes in mice and rats.
Criteria used to assess the effects of the p)retreatment re,gimies Body weigqht. The body weights of treated and control mice Aere monitored daily from the beginning of pretreatrnent to the end of each experimnent. i.e. Days 3-or 4-9 inclusive.
Liver weight. In some experiments the effect of the pretreatment regimes on liver weight wNas determined on the same day as the pharmacokinetic experiment (Day 9). Liver weight was expressed as a, percentage of total body wveight.
Pentobarbitone sleeping-tim?e. In some experiments pentobarbitone sleepinig-times wvere also determined on Day 9. Sodium pentobarbitone wvas diluted to 6 mg/ml in HBSS and mice were inijected with 10 ml/kg i.p., to give 60mg/kg pentobarbitone. Sleeping-time was defined as the time required for mice to regain the righting reflex (Stevenson & Turnbull, 1968 Control studies showed that the concentrations of MIS and Ro 05-9963 in whole blood and plasma were identical. The two methods therefore gave entirely comparable results.
Urinary excretion. Groups of 5 mice were contained in a Urimax metabolism cage and urine was collected for 24 h after MIS injection. Urine A-as analysed for MIS and Ro 05-9963 and their 3-glucuronidase-hydrolysable conjugates, as described previously (Workman et al., 1978b; White et al., 1979 (Workman et al., in preparation) . However, for up to 6-8 h after a dose of 1 g/kg i.p., the elimination of MIS from l)lood and plasma approximates closely to first-order kinetics (see Results). The apparent elimination rate constant (kel) is given by the slope of the plot of log MIS concentration against time. The apparent half-life (tl) is given by ln2/kei. Where the individual bleeding method w-as used, t, wAas calculated for individual mice. In experiments a-here mice were killed at each sampling time, t wA-as calculated for the w-hole group; this mnethod wN-as also used to calculate t for the elimination of MIS from tumour and brain.
The area under the curve (AUC) of plasma, blood or tissue concentration versus time was estimated by Simpson's rule. As for t , AUC was estimated for individual mice or for groups.
Where peak concentrations are reported, these are the maximna observed, wN-ith the earliest sample being at 15 or 30 min. More detailed absorption studies have shown that for the 1 g/kg i.p. dose a broad peak is observed in the blood betw!een 15 and 60 mill.
Tissue/plasma concentration ratios were calculated by dividing the tissue concentration by the plasma concentration measured for the same time in the same nmouse.
Measurement of body tem)perature
In experiments to determine the effects of phenobarbitone and phenytoin pretreatment on the decrease in body temperature after MIS injection, core body temperatures were measured with a rectal thermistor probe connected to an externally calibrated electric thermometer (Light Laboratories Limited, Brighton).
Statistical analysis
Lines of best fit, -with standard errors, were calculated by least-squares linear-regression analysis.
Confidence limits and the significance levels of differences betwreen various treatment groups were calculated using Student's t distribution.
RESULTS
Effects of phenobarbitone and phenytoin on body and liver weight and pentobarbitone sleeping-time Body weight. The phenobarbitone pretreatment regime caused some initial weight loss, but this did not exceed 10% and was normally completely regained by Day 9. Pretreatment with phenytoini, saline or HBSS caused little or no weight loss.
In our BALB/c mice, the approximate acute LD50 values for single drug doses were between 150 and 200 mg/kg for phenobarbitone and 200-240 mg/kg for phenytoin.
Liver weight and pentobarbitone sleepinytime.-In some experiments liver weight and barbiturate sleeping-time were measured as indices of the extent of induction of microsomal drug-metabolizing enzymes (Marshall & McLean, 1969; Stevenson & Turnbull, 1968; Gerber & Arnold, 1969) . Table V with those in Table III shows that the pharmacokinetics are similar in normal and tumourbearing mice, and that phenobarbitone has the same effect in both.
Comparison of tumour, brain and plasma levels in control and treated mice yielded some interesting findings which are discussed below. Fig. 3 shows that for both saline and phenobarbitone pretreated groups, tumour AIIS concentrations are similar to the corresponding brain concentrations during the period 1-6 h after injection. The mean (+ s.e.) tumour/plasnma ratios in saline and phenobarbitone pretreated mice were 0 54 + 009 and 0 50 + 010 respectively. Corresponding values for the brain/plasma ratios were 0 51 + 0404 and 0 48 + 0409 for saline and phenobarbitone groups respectively. Howvever, the 15min data showed consistently that the tumour equilibrates with the plasma more slowly than does the brain. were 0-59+0 04 and 0 49+0 03 for saline and phenobarbitone groups respectively. The brain/plasma ratios for the metabolite, on the other hand, were generally about half those for the parent drug; mean values ( ± s.e.) were 0 24 + 0 05 and 0 27 + 001 for saline and phenobarbitone groups respectively. As a consequence, the AUCO_6h for Ro 05-9963 in the brain was considerably lower than that in the tumour (Table V) .
The effects of pretreatment with phenobarbitone on the kinetic parameters for brain and tumour (Table V) Phenytoin.-Two experiments were performed on EMT6 tumour-bearing mice, and the combined data are summarized in Table VI . Comparison with Table IV shows that, like phenobarbitone, phenytoin has similar effects on normal and tumour-bearing mice.
Comparison of Tables V and VI reveals that, in general, the effects of phenytoin on the pharmacokinetic parameters for brain and tumour tissues were very similar to those caused by phenobarbitone. However, two points are worthy of note. Firstly, the tissue/plasma MIS ratios in these experiments were around 0 3, which is rather lower than in the phenobarbitone experiments (Table V) (Table VT) .
Effects ofphenobarbitone on MIS pharmacokinetics in B1.0 mice bearing the MC6B tumoitr Two experiments were carr:ied out to determine the effects of phenobarbitone in BlO mice bearing the MC6B tumour. The combined data are summarized in Fig. 5 and Table VII. The results were very similar to those obtained for BALB/c mice bearing the EMT6 tumour. There are, however, 3 interesting differences.
Firstly Effects of phenobarbitone and phenytoin on MIS-induced temperature loss Little change in body temperature was seen when BALB/c mice pretreated with saline, phenobarbitone or phenytoin were injected with 40 ml/kg HBSS (Fig. 6) . Also, the temperature profiles were identical to those for mice receiving neither pretreatment nor HBSS (data not shown). In contrast, all 3 pretreated groups showed a marked decrease in temperature after I g/kg MIS. However, compared to the saline group, the phenobarbitone and phenytoin groups exhibited a slightly smaller decrease, and a much quicker return to normal temperature. Similar results were obtained in several repeat experiments. Effect of phenobarbitone and phenytoin on MIS acute LD50
Two separate experiments were carried out, to investigate the effect of pretreatmnent with phenobarbitone, phenytoin and the saline vehicle on the acute LD50(7d) of MIS in BALB/c males. Similar results were obtained in the two experiments, and the analysis of the combined data is summarized in Table IX . It may be seen that whereas the saline vehicle was without effect (P> 1), both phenobarbitone and phenytoin caused the LD50 to be significantlv increased (P < 0 001).
DISCUSSION
In the present paper, we have shown that pretreatment of mice with phenobarbitone or phenytoin profoundly affects :34 7 the pharmacokinetics of the hypoxic cell radiosensitizer MIS. Pretreatment with these agents shortened the apparent t, for MIS elimination from blood or plasma by 35-600/, and this was associated with a concomitant 1P5 to 2-fold increase in the circulating concentrations of the 0-demethylated metabolite Ro 05-9963. Both phenobarbitone and phenytoin are known potent inducers in vivo of hepatic microsomal drug-metabolizing enzymes, particularly the mixed-function oxidases which catalyse, among many other reactions, the 0-demethylation of xenobiotics (Conney, 1967; Parke, 1968) . We also observed that pretreatment with phenobarbitone or phenytoin caused the liver/ body weight ratio to be increased, and barbiturate sleeping-time to be decreased. These are among the classical effects of agents which elevate microsomal mixedfunction oxidase activities in vivo (Marshall & McLean, 1969; Stevenson & Turnbull, 1968; Gerber & Arnold, 1969) . The preceding data therefore strongly suggest that the reduced MIS ti after pretreatment with phenobarbitone or phenytoin is due to the increased metabolism of MIS to Ro 05-9963 by hepatic microsomal mixed-function oxidases.
Previous studies at the same drug dose
(1 g/kg) have shown that the t. of MIS is prolonged after bilateral kidney ligation (Brown et al., 1979) . Taken together with the present data, it can be seen that the MIIS t, at this dose is dependent upon both metabolism and urinary excretion. It is interesting to note, however, that the urinary excretion of MIS, Ro 05-9963, and their respective glucuronides, was not affected by phenobarbitone or phenytoin. Urinary excretion of these compounds accounted for only 15-420% of the administered dose (1 g/kg), and this was similar to the value reported by Flockhart et al. (1978a) for normal mice given 100 mg/kg.
It is apparent that changes in MIS t, after enzyme induction are not reflected in the urinary excretion profile. This may be due to the involvement of other metabolic pathways which may not be rate-limiting with respect to the systemic elimination of MIS. We have seen that MIS pharmacokinetics are similar in normal and EMT6 tumour-bearing BALB/c mice. AMoreover, the MIS t. was decreased after enzyme induction both in BALB/c mice with EMT6 tumours and Bi1 mice with MC6B tumours. This is of interest in view of previous reports (see Sladek et al., 1978) that hepatic microsomal mixed-function oxidase activity may be reduced in animals with primary or transplanted solid tumours.
Despite the marked decrease in MIS t, after phenobarbitone or phenytoin, the peak blood (or plasma) MIS concentrations were reduced only slightly, if at all. In contrast, the blood (or plasma) MIS AUC was consistently decreased by 25-6000'. The enhanced metabolism of MIS caused by the enzvme inducers resulted in an increased blood (or plasma) AUC for the metabolite Ro 05-9963, amounting to 10-60% in BALB/c mice and 100% in the B IO strain. Despite this increase, the blood (or plasma) AUC for total 2-nitroimidazole (MIS + Ro 05-9963) was always reduced by 20-40% after enzyme induction.
XVe have shown that EMT6 tumour/ plasma ratios for both MIS and Ro 05-9963 were constant (within experiments) at 0-3-0-6. Values obtained for the MC6B tumour were also constant, though higher (-0 7). For both tumours, we found that the tumour/plasma ratios were not affected when the MIS t, was shortened after enzyme induction. This complements the previous demonstration that this ratio was unaltered when the t. for MIS or injected Ro 05-9963 was prolonged after kidney ligation (Brown et al., 1979) . The brain/plasma ratios for both MIS and (Adams et al., 1976) since lipophilicity is the major factor affecting the penetration of unionized compounds of low molecular weight across the blood-brain barrier (reviewed by Bradbury & Davson, 1964) . This would suggest that if brain concentration contributes to the neurotoxicity of nitroimidazoles (see below) Ro 05-9963 might be less toxic than MIS. In mice, Ro 05-9963 has a higher LD50 than MIS, and at equal tumour concentrations they are equally good radiosensitizers (Brown et al., 1979) . Ro 05-9963 therefore may have potential for clinical use.
As for the peak plasma concentrations, phenobarbitone and phenytoin did not alter the peak MIS concentrations for either tumour or brain. However, apparent t, values for the elimination of MIS from these tissues were shortened. Moreover, the AUC for both MIS and total 2-nitroimidazole were reduced, although the AUC for Ro 05-9963 was increased in some experiments.
Having established that the pharmacokinetics of MIS are indeed altered by phenobarbitone and phenytoin the question arises as to whether these interactions alter the toxic and therapeutic effects of MIS. Taking first the radiosensitization of hypoxic cells by MIS, there is fairly good evidence from animal experiments that this property is a function of the concentration of intact nitroimidazole in the tumour at the time of radiation (McNally et al., 1978) . We have shown that the peak tumour MIS concentration is not altered by the enzyme inducers. Thus if radiation is given at the time of the peak concentration, the radiosensitization should not be affected. Of course, this presupposes that pretreatment with the enzyme inducers dose not have an adverse effect on the radiation response involving mechanisms 24 unrelated to the effects on MIS disposition kinetics.
For the present discussion it is convenient to consider 3 types of toxicity displayed by MIS and related nitroheterocyclics:
( It appears that oxidative metabolism has not been considered previously as contributing to MIS toxicity. O-demethylation is catalysed by microsomal mixedfunction oxidases, proceeding via the intermediate methylol which breaks down spontaneously to the demethylated metabolite and formaldehyde (Fig. 7A) (Parke, 1968) . Previous studies with melamines, such as hexamethylmelamine (HMMi) implicated the N-methylols or formaldehyde as possible toxic species (Rutty & Connors, 1977; Rutty et al., 1978) . This is especially pertinent as HMM also causes neurotoxicity in man. It is also relevant that the hydroxymethyl metabolite of metronidazole is considerably more mutagenic than the parent drug (Connor et al., 1977 Willson, 1977; Foster, 1978) . Reduiction of the nitro group to the amine will proceed via the nitroradical anion, nitroso, hydroxylamine and other potentially cytotoxic intermediates (Fig. 7B ) (Wardman, 1977; Willson, 1.977; Whitmore et al., 1978) . The unstable amine has been detected in mouse tumours and human urine (Flockhart et al., 1978a, b; Varghese et al., 1976 T'reatment with microsomal-enzyme inducers cauises increased concentrations of cytochrome P-450, NADPH-cytochrome-c reductase and phosphatidyl choline, which together comprise the mixed-function oxidase enzyme complex (Conney, 1967; Lu & West, 1978) . Cytochrome P-450 and NADPH-cytochrome-c reductase catalyse both oxidative and reductive reactions, including the reduction of nitroheterocyclics (Gillette, 1971 (Gillette, , 1977 . These latter reactions are also carried out by soluble enzymes, including aldehyde oxidase and xanthine oxidase (Gillette, 1 971, 1 977) and collectively these enzymes comprise the tissue "nitroreductase".
Phenobarbitone pretreatment in vivo increases nitroreduction by liver microsomes incubated under anoxic conditions in vitro (Conney, 1967) . However, this is strongly inhibited by oxygen and may not occur in well oxygenated normal tissues in vivo (Gillette, 1971) . Thus it is unlikely that microsomal-enzyme inducers wvill increase nitroreduction in normal tissues. In fact, the increased oxidative metabolism is more likely to protect against any cytotoxicity op)erating via nit,roreduction.
Decreased nitroreduction may be a factor involved in the increased MIS LD50 in mice pretreated with phenobarbitone and phenytoin. However, two other possibilities should be considered. Firstly, pretreatment with these agents may produce a physiological tolerance to MIS unrelated to metabolic factors. However, the involvement of such an effect is normally postulated only in cases where metabolic factors cannot be implicated, whereas in the present studies an increased oxidative metabolism has been clearly demonstrated. The second, and more likely, possibility is that the AUC for MIS (or total 2-nitroimidazole) may be responsible for the lethal effect: in this case the increased LD50 would be explained by the decreased AUC. Likewise, the more rapid clearance of MIS from the brain may explain the quicker return to normal body temperature.
There is some suggestion that the doselimiting neuropathy of MIS in man is related to the AUC (Dische et al., 1977; Saunders et al., 1978) . If so, the toxicity might be reduced by using microsomal enzyme inducers to decrease the AUC.
It is certain that many cancer patients receiving MIS will also require other medications, including microsomal-enzyme inducers. Phenobarbitone and phenytoin, for example, are frequently administered to brain-tumour patients. The present studies provide pharmacological evidence that the radiosensitization by MIS is unlikely to be reduced by such induction and, in addition, that the toxicity might be decreased. Our preliminary studies in man suggest that the MIS ti and AUC are both reduced by phenytoin therapy.
